Table 1.

Demographic and Clinical Characteristics of the Patients and Treatment Details.^*

Variable	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5
Demographic or clinical characteristic
Age (yr)	61	60	65	62	83
Sex	Male	Male	Male	Male	Female
Type of cardiomyopathy	Nonischemic	Ischemic	Nonischemic	Nonischemic	Ischemic
NYHA class	IV	III	IV	IV	IV
Left ventricular ejection fraction (%)	37	17	22	26	15
No. of previous antiarrhythmic drugs	3	3	3	4	2
No. of previous catheter ablations	1	0	2	4	0
No. of induced episodes of ventricular tachycardia	2	1	0	5	6
No. of episodes of ventricular tachycardia 3 mo before treatment	30	20	5	2210	4312
Treatment
Ablation target region	Anterior basal left ventricle	Anterolateral basal left ventricle	Inferior left ventricle	Left ventricle outflow and septum	Inferolateral mid left ventricle
blation volume (ml)	51.3	17.3	44.5	53.0	81.0
Treatment time (min)	12	11	14	12	18
Length of hospital stay after treatment (days)	2	1	2	2	1
Antiarrhythmic medication at discharge	Amiodarone, mexiletine	Amiodarone, mexiletine	Amiodarone, mexiletine	Amiodarone, mexiletine	Amiodarone, mexiletine
No. of episodes of ventricular tachycardia during 6-wk blanking period	0	3	0	355	322
No. of episodes of ventricular tachycardia 10.5 mo after blanking period	3	0	1	0	NA
No. of additional ablation procedures performed by 1 yr	0	0	0	1 at 4 wk	NA
Antiarrhythmic medication at 1 yr	None	None	Amiodarone (restarted at 9 mo)	None	NA

^*NA denotes not applicable because the patient died 3 weeks after treatment, and NYHA New York Heart Association.